Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells

摘要: Human embryonic stem cells (hESCs) and induced pluripotent (iPSCs) provide remarkable cellular platforms to better understand human hematopoiesis develop clinically applicable hematopoietic cell–based therapies. Over the past decade, hESCs have been used characterize molecular mechanisms underpinning differentiation of progenitors mature, functional cells. These advances are now poised lead clinical translation hESC- iPSC-derived for novel therapies in next few years. On basis areas recent success, initial use derived from will probably be transfusion (erythrocytes platelets) immune (natural killer cells). In contrast, efficient development isolation capable long-term, multilineage engraftment still remains a significant challenge. Technical, safety, regulatory concerns related applications PSCs must appropriately addressed. However, proper consideration these issues should facilitate not inhibit new This review outlines current status cell what obstacles surmounted bring “bench bedside.”